The effect of acetazolamide on passive and active transport of fluorescein across the blood-retina barrier in retinitis pigmentosa complicated by macular oedema
- PMID: 9865617
- DOI: 10.1007/s004170050175
The effect of acetazolamide on passive and active transport of fluorescein across the blood-retina barrier in retinitis pigmentosa complicated by macular oedema
Abstract
Background: The carbonic anhydrase inhibitor acetazolamide (AZM) reduces macular oedema in some patients with retinitis pigmentosa. To better understand the oedema-reducing effect of AZM, the effect of AZM on passive permeability and active transport of fluorescein across the blood-retina barrier was studied in patients with retinitis pigmentosa and varying degrees of macular oedema.
Method: The selection of patients was based on an introductory examination including vitreous fluorometry for qualitative assessment of the vitreous. Macular oedema was graded by fluorescein angiographic leakage. The effect of AZM on the transport properties of the blood-retina barrier was determined by differential spectrofluorometry, in a randomised, double-masked, cross-over study, comprising 2 weeks' treatment with AZM (500 mg/day) and 2 weeks' treatment with placebo. The penetration ratio, defined as the ratio between vitreous concentration 3 mm in front of the retina and the plasma integral, was determined for fluorescein and its metabolite fluorescein glucuronide at 30-60 min and at 120 min after fluorescein injection. Passive permeability and unidirectional permeability in the direction vitreous to blood, due to outward active transport of fluorescein, were determined in those cases where the curves for vitreous concentration of fluorescein could be fitted to a mathematical model. Visual acuity was tested by use of ETDRS standard logarithmic charts.
Results: Twenty-two patients volunteered to participate in the study. Signs of significant vitreous detachment/liquefaction caused the exclusion of ten patients after the introductory examination. Nine patients with approximately intact vitreous and varying degrees of oedema completed the cross-over study. AZM treatment was related to a decrease in the penetration ratio of 21% for fluorescein (P=0.01) and of 22% for fluorescein glucuronide (P=0.004). Passive permeability and unidirectional permeability were determined in seven patients. AZM caused a decrease of 27% in the passive permeability of fluorescein (from 1.1 x 10(1) nm/s, P=0.031), and a 95% increase in unidirectional permeability of fluorescein (from 1.2 x 10(2) nm/s, P=0.047). AZM led to a reduction in the grade of macular oedema as determined by fluorescein angiography in three out of seven patients. Only small improvements (< or =5 letters) in visual acuity were noted.
Conclusion: The present study indicates that the oedema-reducing effect of AZM is due to decreased leakage and stimulated active transport across the blood-retina barrier.
Similar articles
-
Effects of acetazolamide on passive and active transport of fluorescein across the normal BRB.Invest Ophthalmol Vis Sci. 1999 Jul;40(8):1770-5. Invest Ophthalmol Vis Sci. 1999. PMID: 10393047 Clinical Trial.
-
Efficacy of dorzolamide hydrochloride in the management of chronic cystoid macular edema in patients with retinitis pigmentosa.Retina. 1997;17(3):222-31. doi: 10.1097/00006982-199705000-00009. Retina. 1997. PMID: 9196934 Clinical Trial.
-
Effect of acetazolamide on outward permeability of blood-retina barrier using differential vitreous flyorophotometry.Curr Eye Res. 2001 Sep;23(3):166-70. doi: 10.1076/ceyr.23.3.166.5461. Curr Eye Res. 2001. PMID: 11803477
-
The role of carbonic anhydrase inhibitors in the management of macular edema.Doc Ophthalmol. 1999;97(3-4):387-97. doi: 10.1023/a:1002143802926. Doc Ophthalmol. 1999. PMID: 10896355 Review.
-
Ocular fluorometry methodological improvements and clinical studies--with special reference to the blood-retina barrier permeability to fluorescein and fluorescein glucuronide.Acta Ophthalmol Suppl (1985). 1993;(211):1-52. Acta Ophthalmol Suppl (1985). 1993. PMID: 8318868 Review.
Cited by
-
[Treatment of pseudophakic cystoid macular edema].Ophthalmologe. 2007 May;104(5):425-6, 428-30. doi: 10.1007/s00347-007-1534-9. Ophthalmologe. 2007. PMID: 17443332 Review. German.
-
Carbonic anhydrase as a model for biophysical and physical-organic studies of proteins and protein-ligand binding.Chem Rev. 2008 Mar;108(3):946-1051. doi: 10.1021/cr050262p. Chem Rev. 2008. PMID: 18335973 Free PMC article. Review. No abstract available.
-
Diabetic macular oedema: a comparison of vitreous fluorometry, angiography, and retinopathy.Br J Ophthalmol. 2002 Mar;86(3):316-20. doi: 10.1136/bjo.86.3.316. Br J Ophthalmol. 2002. PMID: 11864891 Free PMC article.
-
Systemic Carbonic Anhydrase Inhibitors in Common Ophthalmic Diseases: A Scoping Review from A Clinical Standpoint.Curr Ophthalmol Rep. 2025;13(1):9. doi: 10.1007/s40135-025-00332-x. Epub 2025 Jul 8. Curr Ophthalmol Rep. 2025. PMID: 40642047 Free PMC article. Review.
-
Efficacy of carbonic anhydrase inhibitors in management of cystoid macular edema in retinitis pigmentosa: A meta-analysis.PLoS One. 2017 Oct 12;12(10):e0186180. doi: 10.1371/journal.pone.0186180. eCollection 2017. PLoS One. 2017. PMID: 29023491 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources